Gonococcal antimicrobial susceptibility surveillance in Europe – 2010
In 2010, 21 EU/EEA Member States participated in the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), testing a total of 1766 isolates.
Euro-GASP 2010 identified a significant increase in the proportion of tested isolates that show decreased susceptibility to cefixime, from 4% in 2009 to 9% in 2010, using a cut-off of &gt;0.125 mg/L. Rates of ciprofloxacin and azithromycin resistance remain high (53% and 7%, respectively).
The rapid increase and spread of decreased susceptibility to cefixime is extremely concerning as cefixime is a recommended therapy for gonorrhoea across Europe, as is ceftriaxone.
Influenza virus characterisation, November 2019
11 Dec 2019 - This is the second influenza characterisation report for the 2019–20 influenza season. As of week 48/2019, 6 887 influenza detections across the WHO European Region had been reported; of which 84% were type A viruses, with A(H3N2) prevailing over A(H1N1)pdm09, and 16% type B viruses, with 123 of 137 (90%) ascribed to a lineage B/Victoria.
HIV/AIDS surveillance in Europe 2019 - 2018 data
28 Nov 2019 - This report has been published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe. The Regional Office developed the overview of the European Region as a whole and validated the figures of the non-member countries of the European Union (EU)/European Economic Area (EEA) and ECDC developed the overview of the EU/EEA countries and validated the EU/EEA figures.
External quality assessment of laboratory performance – European Antimicrobial Resistance Surveillance Network (EARS-Net), 2018
22 Nov 2019 - This report provides an analysis of the external quality assessment (EQA) performance with antimicrobial susceptibility testing (AST) of laboratories participating in the European Antimicrobial Resistance Surveillance Network in 2018. A total of 860 laboratories (1 – 114 per country) from 30 EU/EEA countries participated in the EQA exercise. Six bacterial strains were used: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecium and Streptococcus pneumoniae.